**Paxlovid Training**

Huge thanks to the team at NES (Leon, Vicky and Richard) and the presenters, Fiona Marra and Alison Boyle, for arranging the training session on Paxlovid.

The session is available to view online on TURAS (open to all registered users)

<https://learn.nes.nhs.scot/59984/pharmacy/cpd-resources/prescribing-of-paxlovid-for-the-treatment-of-covid19>

A copy of the power point presentation is attached.

**Prescribing Paxlovid in Moderate Renal Impairment**

A query that came up during the training session was whether Paxlovid can be prescribed in patients with ***moderate***renal impairment. The Paxlovid [SPC](https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fregulatory-approval-of-paxlovid&data=04%7C01%7CLeon.Zlotos%40nhs.scot%7C45845ac573fc43f57e3208d9e808f373%7C10efe0bda0304bca809cb5e6745e499a%7C0%7C0%7C637795947399400946%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=71WOuuwpIOOPBLjYTMmJv8atbbb36qdoqwWPssptv8k%3D&reserved=0) advises that no dose adjustment is needed in patients with mild renal impairment. In patients with moderate renal impairment (stage 3 chronic kidney disease), the dose of Paxlovid should be reduced to PF-07321332/ritonavir 150 mg/100 mg (1 tablet of each) twice daily for 5 days. Paxlovid is not recommended in patients with severe renal impairment or with renal failure (stages 4-5 chronic kidney disease).

Although there is provision in the SPC for dose adjustment in patients with stage 3 chronic kidney disease, the UK-wide access policy advises that Paxlovid should ***not*** be prescribed if the patient has stage 3 chronic kidney disease and recommends that instead, an alternative treatment option is considered for this patient group. If a reduced dose was required, to meet an individual patient need, care should be taken to ensure this is appropriately documented and clearly communicated in the prescribing instruction to minimise the risk of dispensing errors.  (*it is not yet clear how different electronic prescribing systems will support prescribing of a reduced dose of PF-07321332)*